DELAWARE
|
|
001-35621
|
|
04-3744954
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
o
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Emerging growth company
|
o
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
|
o
|
Exhibit No.
|
Description
|
|
|
16.1
|
Letter from Grant Thornton LLP, dated April 18, 2017 to the Securities and Exchange Commission.
|
|
|
GLOBUS MEDICAL, INC.
|
|
|
(Registrant)
|
|
|
|
Dated:
|
April 18, 2017
|
/s/ DANIEL T. SCAVILLA
|
|
|
|
|
|
Daniel T. Scavilla
|
|
|
Senior Vice President,
|
|
|
Chief Financial Officer
|
Exhibit No.
|
Description
|
|
|
16.1
|
Letter from Grant Thornton LLP, dated April 18, 2017 to the Securities and Exchange Commission.
|